IL22 and histiocytic sarcoma: These compounds target the immune mediators which are responsible for the inhibition of pro-inflammatory cytokine synthesis such as: IL-1β, IL-6, IL-12, IL-17, IL-22, IL-36, TNF-α, IFN- γ, which are commonly involved in the acute and chronic stages of HS.